BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. - Wikidata - awgldk - TriplyDB

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

http://www.wikidata.org/entity/Q36732681

about

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines Negative feedback regulation of the ERK1/2 MAPK pathway Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.Senescent tumor cells lead the collective invasion in thyroid cancer.The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.Molecular pathogenesis and mechanisms of thyroid cancer Differential diagnosis of thyroid nodules using fine-needle aspiration cytology and oncogene mutation screening: are we ready?Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis?Local anesthetics induce apoptosis in human thyroid cancer cells through the mitogen-activated protein kinase pathway Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.B-Raf mutation and papillary thyroid carcinoma patients.Evolving approaches to patients with advanced differentiated thyroid cancer Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.Integrating BRAF/MEK inhibitors into combination therapy for melanoma.New agents in the treatment for malignancies of the salivary and thyroid glands.Molecular pathology of thyroid cancer: diagnostic and clinical implications.Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements Molecular markers of aggressiveness of thyroid cancer.Iodine mediated mechanisms and thyroid carcinoma.Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.BRAF mutation testing in clinical practice.The biology and clinical development of MEK inhibitors for cancer.Advances in thyroid cancer treatment: latest evidence and clinical potential.Activation and involvement of Ral GTPases in colorectal cancer.

P2860

Q24303940-F241ACE5-D3D2-4051-B948-A4D4AF25788E Q27851932-EA603C59-7B4F-411A-8081-BA74A1FE4818 Q28079202-5B248A11-0211-423F-813E-AE5EF6C619A2 Q28476362-C319C5B9-0D08-4666-A407-82100E9430AA Q28730199-420DE222-F8A4-4538-A804-97EA45863545 Q33691759-61BE27DB-605E-4E6F-902B-D8EB55B5AF59 Q33702243-EBA9339E-8321-49D1-BAC7-B8EB509E06A9 Q33770769-116CF392-B951-42FA-A461-D8566D03BA36 Q33770842-F6DDC01F-054A-4A4C-BA0F-3A89E58EA508 Q33801421-D9A278C4-73F6-4D67-A0B2-6693E43F386A Q33839230-0039E069-7CDF-4073-A3A2-3D12C538188D Q33909942-C0862AF1-EE50-40E7-9C91-BECBCCFD109B Q33945648-8F0F5A26-A076-44B8-8192-60F9793C4896 Q34109756-EF0CCCF0-0924-4DDF-BBCF-EF8EDA5B6E26 Q34272199-BBE41500-02CD-461B-A06B-772089A1A01D Q34329018-B25FB065-A0CB-4E8D-B62B-E6395AFEE040 Q34363745-5E1D982A-7DF3-41F0-BCE6-DE0FA8AD0038 Q34533804-A1E391EF-4405-40F9-965F-11189DBFFC9A Q35059440-549D17FA-243F-4CCA-951D-0E0E05A2F1FD Q35107625-CCF02A8E-26C6-408C-8CEA-C794294D0B64 Q35578577-B07E54B4-52E9-4B3E-90C4-B42C8BD1DED8 Q35914464-F9A16C02-063D-4AFC-BECA-A567605F6782 Q36094108-690D9262-18E3-4EB3-A9F1-254E284B019B Q36741221-45F6F55B-DA2A-46FA-A0A8-CCB4FE45C0D5 Q36864736-DF7E9828-2ACA-40D0-9AC9-206B93D6DD0B Q36971972-C89209E5-083E-4790-98EB-E50B061349D0 Q36976683-663654FD-94F9-4F36-8DC2-C565F9071E25 Q37135238-C78C4CA2-B522-4E71-89B2-0F10463AB4D0 Q37137859-8B9B9AD2-DB19-44FF-A7B0-2221EBE1C33B Q37337504-A5482F3B-175F-4E9D-8B14-F1858E0D2346 Q37379562-782542D2-78D2-4117-B81C-2795CB7522F7 Q37505185-1BAAB3D4-5175-47AB-840C-3E5D3845498E Q37544168-547A4365-6164-407B-B585-82EF05336AA3 Q37643737-7E21E3F7-7F74-400F-B683-450782E0A6D4 Q37753517-7AA8F222-1A5B-49FB-B4C9-9C406907CF25 Q37988566-70396C21-6185-41B0-8228-0A740D144414 Q37988572-B3EEFD6D-3CD6-48FD-9092-4ADD63F4572C Q38270129-95F55D65-56F6-4B67-9365-A6C186EAF42A Q38305056-76FC3DDC-4C3A-4AD1-8886-B7E3D02BE224 Q38338335-892561DF-7A4F-4349-A8DD-6136F40594DC

P2860

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

http://www.wikidata.org/entity/Q36732681

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

BRAFV600E mutation is associat ...... in thyroid cancer cell lines.

@ast

BRAFV600E mutation is associat ...... in thyroid cancer cell lines.

@en

type

label

BRAFV600E mutation is associat ...... in thyroid cancer cell lines.

@ast

BRAFV600E mutation is associat ...... in thyroid cancer cell lines.

@en

prefLabel

BRAFV600E mutation is associat ...... in thyroid cancer cell lines.

@ast

BRAFV600E mutation is associat ...... in thyroid cancer cell lines.

@en

P1433

Q36732681-E27F8995-F90E-4BFA-894C-8C6E3F33825C

P1476

Q36732681-EB9159EB-6B64-415E-9160-ABE666CD5748

P2093

Q36732681-2BF9E93B-EA99-4C9E-9063-D925BB5819C8

Q36732681-434C41F0-78BD-4DD0-A8B8-79D454C39205

Q36732681-97E8E53D-5337-4F8B-805A-8B2E980A204F

Q36732681-A3AFF205-779E-4009-9D75-B6458AD5CE72

Q36732681-AF01BEC0-6D67-482D-87B9-A49A873AD75E

Q36732681-BF1F4DB5-194E-4CFB-A090-5B086829AEB3

Q36732681-C93FD561-07F6-48C1-B44B-667D1FC9C580

Q36732681-D070DB54-F78D-4072-83D8-3AAA3F93ECAC

Q36732681-ECFDCA17-F1F4-4936-BDC9-F49282486062

P2860

Q36732681-01CF606D-18C8-4D83-9BDC-CB2E8DC794CD

Q36732681-09953B22-5183-4A89-9FF1-EB05F5AC4D00

Q36732681-09D2C695-B8B3-4ED8-9FBC-4890BF8EB3BE

Q36732681-1DEE1B04-F791-485B-B4F5-D2B91A55442C

Q36732681-2AFFBE71-CD5C-4024-A231-812B60944CBF

Q36732681-3FBCA2D3-CFBF-4BE4-BD7E-31ADC2F8A8BC

Q36732681-495B4A9A-42C5-4408-B257-0241D73850EC

Q36732681-4B13B8CD-3311-4A1E-ADD0-B2FF39E0AD32

Q36732681-4CE86FD1-078E-4729-9DCA-4CFB28C2D8EE

Q36732681-5579D8A3-D55C-41B7-A72F-DCCA4B4419BF

P304

Q36732681-7BCFDD01-B97F-42A3-9376-14D1AE79D86B

P31

Q36732681-626C0070-7CA8-4C82-B4C3-3DC152C9489C

P356

Q36732681-5571DD0D-4BDA-4456-917C-D18FE2A0330A

P407

Q36732681-FAC5497C-BA50-4EF6-928F-8ACAC19313E8

P433

Q36732681-65B55188-1145-4107-AD11-CDFF88E4971C

P478

Q36732681-4347DDB0-6489-49B6-92D4-EA0D67BE7D8A

P577

Q36732681-3D72F9AC-14B8-4BAD-A42F-72767FDE071C

P5875

Q36732681-CA6A72A8-8907-4E52-861C-91C06A226556

P698

Q36732681-2F449653-6C9C-43BC-A2BF-016EB785D719

P932

Q36732681-90D01F0C-81E8-479A-B023-DAC67A4F8987

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

BRAFV600E mutation is associat ...... in thyroid cancer cell lines.

@en

P2093

Christine A Pratilas

http://www.w3.org/2001/XMLSchema#string

David Solit

http://www.w3.org/2001/XMLSchema#string

Jacqueline E Baumgartner

http://www.w3.org/2001/XMLSchema#string

James A Fagin

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Knauf

http://www.w3.org/2001/XMLSchema#string

Miriam Benezra

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

Rebecca Leboeuf

http://www.w3.org/2001/XMLSchema#string

Roberta Malaguarnera

http://www.w3.org/2001/XMLSchema#string

P2860

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

Mutations of the BRAF gene in human cancer

The genomic landscapes of human breast and colorectal cancers

p21-activated kinases in cancer

Regulation and role of Raf-1/B-Raf heterodimerization.

BRAF mutation predicts sensitivity to MEK inhibition

TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.

Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase

P304

2194-2201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2007-2825

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5470269

http://www.w3.org/2001/XMLSchema#string

P698

18381570

http://www.w3.org/2001/XMLSchema#string

P932

2435640

http://www.w3.org/2001/XMLSchema#string